CytomX Therapeutics posted a quarterly EPS of -$0.09, missing the -$0.08 consensus, while revenue collapsed to $1.4 million from $18.7 million a year earlier. The miss highlights accelerating cash burn and underscores the importance of upcoming Varseta‑M trial data for investors.
Key Highlights
- CytomX reported a loss per share that missed consensus expectations.
- Revenue for the quarter plunged to $1.4 million, down from $18.7 million a year earlier.
- Cash and investments stood at $330.3 million, excluding a recent $37.0 million Regeneron payment.
CytomX Therapeutics (NASDAQ: CTMX) reported earnings that fell short of consensus expectations, posting an earnings miss while revenue shrank dramatically to $1.4 million from $18.7 million a year earlier. The company’s cash balance stands at $330.3 million, not counting a recent $37.0 million payment from Regeneron, and short interest has risen, reflecting heightened market scrutiny. These figures illustrate a tightening financial profile that places considerable pressure on near‑term clinical milestones.
EPS Miss and Revenue Decline
The earnings release showed a loss per share that missed the consensus forecast. Total revenue for the quarter was $1.4 million, a steep decline from $18.7 million reported in the same quarter of the prior year. The drop stems from the completion of performance obligations tied to collaborations with Bristol Myers Squibb and reduced activity in the Astellas partnership.
Operating expenses rose to $25.2 million, widening the gap between cash outflows and incoming revenue. The combination of a negative earnings surprise and a revenue plunge signals an urgent need for cash‑generating milestones, heightening the relevance of upcoming trial readouts.
Cash Position and Regeneron Deal
Cash and investments stood at $330.3 million at June 30, 2026, providing runway into the second half of 2028. This balance excludes a $37.0 million target‑selection payment received from Regeneron in July 2026 for two new programs. The Regeneron collaboration now covers up to $4.0 billion in potential milestones, underscoring the strategic value of the partnership.
However, operating expense growth of $5.3 million year‑over‑year, driven primarily by $4.3 million in additional research and development spending, offsets some of the cash advantage. Investors must weigh the cash cushion against rising spend, recognizing that continued burn could erode liquidity before the next financing event.
Pipeline Progress and Market Context
CytomX advanced its Varseta‑M (CX‑2051) program, completing enrollment of 113 patients across dose‑escalation and optimization cohorts, with 40 patients reaching the targeted dose range of 8.6 mg/kg and 10 mg/kg. A Phase 1 data update is slated for the end of 2026, feeding into FDA discussions about a first registrational study slated for early 2027. Combination trials with bevacizumab are ongoing, and expansion into gastric, GEJ, PDAC, and BTC indications will begin in Q3 2026.
CX‑801, a masked interferon alpha‑2b, continues its Phase 1 evaluation in melanoma, with dose levels surpassing those of unmasked interferon‑α2b.
Upcoming Catalyst
The company will host a conference call on August 6, 2026, at 5 p.m. ET to discuss the quarter’s results and provide further detail on the Varseta‑M development timeline. The end‑of‑2026 Phase 1 data update for Varseta‑M is a key catalyst that could reshape revenue expectations and influence cash burn dynamics. Successful data could accelerate the initiation of the first registrational study in H1 2027, while any setbacks may prolong reliance on external financing.
Investors should monitor the call for guidance on trial milestones and the integration of the Regeneron payment into the balance sheet.
Analysis based on the Form 8-K filed 6 August 2026; figures verified against the filing and live market data.
This article is for informational purposes only and does not constitute financial advice. Please consult a licensed financial adviser before making investment decisions.






Please wait processing your request...